Laurus Labs Limited (LAURUSLABS.NS)
INR 628.05
(0.18%)
INR 628.05
(0.18%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 3.94 Billion INR | -69.65% |
| 2022 | 12.94 Billion INR | 10.18% |
| 2021 | 11.75 Billion INR | -13.0% |
| 2020 | 13.5 Billion INR | 252.51% |
| 2019 | 3.83 Billion INR | 78.26% |
| 2018 | 2.14 Billion INR | -26.5% |
| 2017 | 2.92 Billion INR | -4.44% |
| 2016 | 3.06 Billion INR | 8.34% |
| 2015 | 2.82 Billion INR | 100.71% |
| 2014 | 1.4 Billion INR | -20.24% |
| 2013 | 1.76 Billion INR | 44.5% |
| 2012 | 1.22 Billion INR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 651.4 Million INR | -53.22% |
| 2024 Q2 | 708.2 Million INR | 8.72% |
| 2023 Q4 | 1.39 Billion INR | 62.97% |
| 2023 FY | 3.92 Billion INR | -69.65% |
| 2023 Q1 | 797.7 Million INR | -60.16% |
| 2023 Q2 | 962.8 Million INR | 20.7% |
| 2023 Q3 | 854.4 Million INR | -11.26% |
| 2022 Q4 | 2 Billion INR | -37.53% |
| 2022 Q1 | 3.85 Billion INR | 14.93% |
| 2022 Q2 | 3.68 Billion INR | -4.4% |
| 2022 FY | 12.94 Billion INR | 10.18% |
| 2022 Q3 | 3.2 Billion INR | -12.93% |
| 2021 Q3 | 2.21 Billion INR | -21.5% |
| 2021 Q2 | 2.81 Billion INR | -16.31% |
| 2021 FY | 11.75 Billion INR | -13.0% |
| 2021 Q1 | 3.36 Billion INR | -19.75% |
| 2021 Q4 | 3.35 Billion INR | 51.44% |
| 2020 Q3 | 3.74 Billion INR | 16.04% |
| 2020 FY | 13.5 Billion INR | 252.51% |
| 2020 Q1 | 2.29 Billion INR | 51.77% |
| 2020 Q4 | 4.19 Billion INR | 12.02% |
| 2020 Q2 | 3.22 Billion INR | 40.67% |
| 2019 Q1 | 374.2 Million INR | -58.31% |
| 2019 FY | 3.83 Billion INR | 78.26% |
| 2019 Q4 | 1.51 Billion INR | 50.3% |
| 2019 Q3 | 1 Billion INR | 11.87% |
| 2019 Q2 | 899.47 Million INR | 140.37% |
| 2018 Q1 | 423.6 Million INR | -48.51% |
| 2018 Q4 | 897.59 Million INR | 99.43% |
| 2018 FY | 2.14 Billion INR | -26.5% |
| 2018 Q3 | 450.07 Million INR | 25.34% |
| 2018 Q2 | 359.08 Million INR | -15.23% |
| 2017 Q1 | 667.28 Million INR | -23.19% |
| 2017 FY | 2.92 Billion INR | -4.44% |
| 2017 Q2 | 824.95 Million INR | 23.63% |
| 2017 Q3 | 563.73 Million INR | -31.66% |
| 2017 Q4 | 822.71 Million INR | 45.94% |
| 2016 Q4 | 868.73 Million INR | 20.81% |
| 2016 Q1 | 602.37 Million INR | 0.0% |
| 2016 FY | 3.06 Billion INR | 8.34% |
| 2016 Q3 | 719.06 Million INR | -12.99% |
| 2016 Q2 | 826.37 Million INR | 37.19% |
| 2015 FY | 2.82 Billion INR | 100.71% |
| 2014 FY | 1.4 Billion INR | -20.24% |
| 2013 FY | 1.76 Billion INR | 44.5% |
| 2012 FY | 1.22 Billion INR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Hester Biosciences Limited | 364.77 Million INR | -982.49% |
| Albert David Limited | 1.33 Billion INR | -195.896% |
| Alembic Limited | 767.77 Million INR | -414.295% |
| Alkem Laboratories Limited | 19.46 Billion INR | 79.711% |
| Alembic Pharmaceuticals Limited | 5.75 Billion INR | 31.425% |
| Bafna Pharmaceuticals Limited | 237.66 Million INR | -1561.442% |
| Bajaj HealthCare Limited | - INR | -Infinity% |
| FDC Limited | 3.03 Billion INR | -30.156% |
| Glenmark Life Sciences Limited | 8.97 Billion INR | 56.025% |
| Gufic Biosciences Limited | 2.89 Billion INR | -36.45% |
| Hikal Limited | 1.49 Billion INR | -164.262% |
| Ind-Swift Laboratories Limited | 2 Billion INR | -96.542% |
| Ind-Swift Limited | 1.22 Billion INR | -222.081% |
| Innova Captab Limited | 2.53 Billion INR | -55.861% |
| Jagsonpal Pharmaceuticals Limited | 214.04 Million INR | -1744.795% |
| Jubilant Pharmova Limited | 5.18 Billion INR | 23.904% |
| Kilitch Drugs (India) Limited | 208.05 Million INR | -1797.909% |
| Lincoln Pharmaceuticals Limited | 1.9 Billion INR | -107.131% |
| Lupin Limited | 27.75 Billion INR | 85.775% |
| Mangalam Drugs & Organics Limited | 27.45 Million INR | -14280.508% |
| Medico Remedies Limited | 277.11 Million INR | -1324.88% |
| Morepen Laboratories Limited | 4.17 Billion INR | 5.396% |
| Nectar Lifesciences Limited | 3.89 Billion INR | -1.491% |
| Orchid Pharma Limited | 2.36 Billion INR | -67.237% |
| Procter & Gamble Health Limited | 2.78 Billion INR | -41.73% |
| RPG Life Sciences Limited | 2.29 Billion INR | -72.255% |
| Solara Active Pharma Sciences Limited | -3.85 Billion INR | 202.484% |
| Sun Pharmaceutical Industries Limited | 104.3 Billion INR | 96.214% |
| Suven Pharmaceuticals Limited | 4.6 Billion INR | 14.303% |
| Themis Medicare Limited | 1.3 Billion INR | -203.015% |
| Unichem Laboratories Limited | - INR | -Infinity% |
| Vaishali Pharma Limited | 6.29 Million INR | -62635.939% |
| Venus Remedies Limited | 534.65 Million INR | -638.538% |
| Wanbury Limited | 1.7 Billion INR | -131.29% |
| Windlas Biotech Limited | 1.29 Billion INR | -203.998% |
| ZIM Laboratories Limited | 1.09 Billion INR | -259.58% |
| Ipca Laboratories Limited | 29.59 Billion INR | 86.659% |
| Aarti Drugs Limited | 7.14 Billion INR | 44.765% |
| Aarti Pharmalabs Limited | 3.12 Billion INR | -26.229% |
| Biofil Chemicals and Pharmaceuticals Limited | 20.65 Million INR | -19015.995% |
| Brooks Laboratories Limited | -72.25 Million INR | 5565.039% |
| Eris Lifesciences Limited | 5.18 Billion INR | 23.798% |
| IOL Chemicals and Pharmaceuticals Limited | 4.94 Billion INR | 20.104% |
| Sigachi Industries Limited | 1.47 Billion INR | -167.902% |
| Sakar Healthcare Limited | 495.5 Million INR | -696.882% |
| Aurobindo Pharma Limited | 104.5 Billion INR | 96.222% |
| Divi's Laboratories Limited | 18.31 Billion INR | 78.435% |
| AstraZeneca Pharma India Limited | 4.47 Billion INR | 11.741% |
| Mankind Pharma Limited | 40.86 Billion INR | 90.338% |
| Sequent Scientific Limited | - INR | -Infinity% |
| Neuland Laboratories Limited | 5.31 Billion INR | 25.752% |
| J. B. Chemicals & Pharmaceuticals Limited | 7.54 Billion INR | 47.643% |
| Glenmark Pharmaceuticals Limited | 6.5 Billion INR | 39.275% |
| Zydus Lifesciences Limited | 45.39 Billion INR | 91.301% |
| Amrutanjan Health Care Limited | 621.02 Million INR | -535.818% |
| Wockhardt Limited | 140 Million INR | -2720.429% |
| Bal Pharma Limited | 214.56 Million INR | -1740.247% |
| Dr. Reddy's Laboratories Limited | 67.72 Billion INR | 94.17% |
| Bliss GVS Pharma Limited | 1.23 Billion INR | -220.763% |
| Par Drugs and Chemicals Limited | 551.58 Million INR | -615.859% |
| Caplin Point Laboratories Limited | 7.22 Billion INR | 45.35% |
| Shilpa Medicare Limited | 3.76 Billion INR | -4.972% |
| Valiant Laboratories Limited | - INR | -Infinity% |
| Ajanta Pharma Limited | 19.67 Billion INR | 79.933% |
| Aarey Drugs & Pharmaceuticals Limited | 2.83 Million INR | -139385.79% |
| Granules India Limited | 6.52 Billion INR | 39.515% |
| Medicamen Biotech Limited | - INR | -Infinity% |
| Syncom Formulations (India) Limited | 249.25 Million INR | -1484.186% |
| Piramal Enterprises Limited | - INR | -Infinity% |
| Torrent Pharmaceuticals Limited | 25.33 Billion INR | 84.415% |
| NATCO Pharma Limited | 25.96 Billion INR | 84.791% |
| Suven Life Sciences Limited | -1.22 Billion INR | 422.119% |
| Krebs Biochemicals & Industries Limited | - INR | -Infinity% |
| Strides Pharma Science Limited | 5.22 Billion INR | 24.44% |
| Indoco Remedies Limited | 1.52 Billion INR | -159.027% |
| Alpa Laboratories Limited | 61.51 Million INR | -6318.922% |
| Lasa Supergenerics Limited | -458 Million INR | 962.13% |
| Sun Pharma Advanced Research Company Limited | -4.11 Billion INR | 195.955% |